Is weight loss a common side effect of lymphoma treatment?

Weight loss can be fairly common around the time of lymphoma diagnosis and during treatment, but patterns vary by lymphoma type and individual factors. [PM13] Some people lose weight early due to the disease and treatment side effects, then gradually regain as treatment controls inflammation and symptoms, while others may have persistent loss that needs active support. [PM14]

Why weight loss happens

• Disease-related changes: Lymphoma and the body’s inflammatory response can reduce appetite, alter metabolism, and lower albumin (a marker of nutritional status), which together promote weight loss. [PM14] Malnutrition and muscle loss (sarcopenia) are linked to poorer tolerance of therapy and outcomes in lymphoma. [PM13]

• Treatment side effects: Chemotherapy and immunotherapy can cause nausea, taste changes, mouth/throat sores (mucositis), early fullness, and fatigue that make eating hard. ^[1] Severe mucositis in high‑dose chemotherapy and stem‑cell transplant can interfere with food intake and contribute to weight loss. [PM21]

• Cachexia versus simple weight loss: Cancer cachexia is a complex syndrome with muscle loss and metabolic changes; it is distinct from weight loss due to low intake alone and often needs multi‑modal care. [PM16] In aggressive B‑cell lymphomas, weight loss at 6 months has been associated with worse survival, underscoring the need to monitor and intervene. [PM14]

Is it “normal”?

It can be expected to some degree, but it is not “benign,” and it deserves attention because addressing nutrition helps you feel better and tolerate therapy more effectively. ^[2] Staying active and eating a balanced diet improves general well‑being and treatment tolerance, even though diet and exercise do not directly kill lymphoma cells. ^[2] Partnering closely with your care team and asking about nutrition support is encouraged to optimize outcomes. ^[3]

How to manage weight loss

Early assessment and monitoring

• Regular check-ins: Track weight weekly during active treatment; flag a drop of more than 5% from baseline or ongoing loss. [PM14]
• Screen for malnutrition/frailty: Your team may use simple tools and lab markers (e.g., albumin, CRP) to gauge risk and guide support. [PM13] [PM14]

Practical nutrition strategies

• Eat small, frequent, high‑calorie, high‑protein meals to meet needs despite reduced appetite; add calorie‑ and protein‑dense ingredients (nut butters, oils, dairy, eggs, tofu, legumes) to everyday foods. ^[4]
• Use oral nutrition supplements (high-calorie/high-protein drinks) when meals aren’t enough, and tailor flavors/temperatures to taste changes to improve intake. [PM18]
• Manage side effects that limit eating:
  • For mouth/throat soreness, choose soft, moist, easy‑to‑swallow foods and avoid irritants; a feeding tube may be considered temporarily if intake is inadequate. ^{[5] [6]}
  • For mucositis during intensive chemotherapy/transplant, preventive oral cooling devices can reduce severity, helping preserve oral intake. [PM21]
  • For nausea, use prescribed antiemetics and bland, dry foods; keep fluids up to avoid dehydration. ^[4]

Activity and rehabilitation

• Gentle resistance and walking can help maintain muscle mass and appetite, supporting recovery and function during therapy. ^[2]

When to escalate support

• Dietitian referral (medical nutrition therapy): Ask for a registered dietitian to build a personalized plan that fits your symptoms and preferences. ^[7]
• Enteral feeding (tube feeding): If weight loss exceeds 5% and eating enough is not possible due to mucositis or swallowing problems, temporary tube feeding may be considered to meet calorie and protein needs. ^{[8] [5]}
• Parenteral nutrition (IV nutrition): Reserved for situations where the gut cannot be used safely; it can meet needs during certain transplant or severe mucositis scenarios but is not routinely helpful when effective tumor control and oral/enteral routes are feasible. ^[8] In older chemotherapy populations, routine parenteral nutrition did not improve survival and sometimes worsened outcomes, so it is used selectively. [PM17]

Appetite and symptom‑targeted medications

• Antiemetics and pain control: Adequate nausea and pain management improve intake. ^[4]
• Appetite stimulants: Some clinicians may consider agents like megestrol acetate or mirtazapine for cancer‑related anorexia after weighing risks/benefits; evidence is mixed and should be individualized. [PM28]

What to discuss with your care team

• Your recent weight trend and appetite, including any barriers like mouth pain, taste changes, nausea, or early fullness. ^[4]
• Nutrition referrals and goals, such as daily protein/calorie targets and specific meal plans or supplements that fit your symptoms. ^[7]
• Side‑effect prevention, including strategies for mucositis and nausea that protect your ability to eat. [PM21] ^[4]
• Activity plans to maintain muscle and stamina during treatment. ^[2]

Outlook

Many people with high‑grade B‑cell lymphoma regain weight over months as inflammation settles and treatment succeeds, especially with proactive nutrition care. [PM14] Still, persistent weight loss should prompt evaluation and support because malnutrition and muscle loss can impact tolerance and outcomes. [PM13]

---

궁금한 점 있으면 언제든 퍼슬리에 물어보세요.